title: Effects of nifedipine on carotid and femoral arterial wall thickness in previously untreated hypertensive patients.
abstract: BACKGROUND
  Experimental and clinical evidence suggests that calcium-channel blockers may retard the atherosclerotic process after long-term treatment. Whether these effects exist after intermediate-term treatment in hypertensive patients is mainly unknown.
  
  
  OBJECTIVE
  To determine the 26-week effects of the long-acting calcium-channel blocker nifedipine on intima media thickness (IMT) in newly found hypertensive patients.
  
  
  METHODS
  Open-label study with blinded end-point analysis.
  
  
  METHODS
  From a population survey, 131 previously untreated mild hypertensives (4 x systolic blood pressure between 160 and 220 mmHg and/or diastolic blood pressure between 95 and 115 mmHg) were included. Patients were treated with long-acting nifedipine 30-60 mg targeted to reach a predetermined drop in blood pressure. Prior to and after 26 weeks of treatment, IMT was measured by ultrasonography in the carotid and femoral artery. The combined mean maximal far wall IMT was used as primary endpoint. Change from baseline was evaluated by paired t-test in an intention-to-treat analysis.
  
  
  RESULTS
  The mean maximal far wall IMT at baseline was 1.03 +/- 0.23 mm, and decreased by 0.078 mm (95% confidence interval, CI 0.044-0.111) after treatment. Regression analysis, including baseline IMT and changes of blood pressure, showed that reduction of IMT was mostly influenced by baseline IMT (p < 0.001; model R2 = 0.1).
  
  
  CONCLUSIONS
  Our observations show that 26 weeks of nifedipine treatment inhibits IMT progression in these newly found hypertensive patients. This effect was mostly seen in arterial walls with highest IMT before treatment, suggesting that patients with highest cardiovascular risk benefit most of antihypertensive treatment.
authors.affiliation: Department of Cardiology, University Hospital Groningen, Groningen, The Netherlands. w.f.terpstra@thorax.azg.nl
authors.forename: Willem F
authors.initials: WF
authors.lastname: Terpstra
authors.forename: Johan F
authors.initials: JF
authors.lastname: May
authors.forename: Andries J
authors.initials: AJ
authors.lastname: Smit
authors.forename: Pieter A
authors.initials: PA
authors.lastname: de Graeff
authors.forename: Harry J G M
authors.initials: HJ
authors.lastname: Crijns
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002339:Carotid Arteries / Q000000981:diagnostic imaging / Q000473:pathology*; D002784:Cholesterol / Q000097:blood; D004452:Echocardiography; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000473:pathology*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D017379:Hypertrophy, Left Ventricular / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D015203:Reproducibility of Results
chemical_list: D002121:Calcium Channel Blockers; D002784:Cholesterol; D009543:Nifedipine